AS-OCT, IVCM find and track epithelial downgrowth after penetrating keratoplasty

Article

Non-invasive imaging modalities, such as high-resolution anterior-segment optical coherence tomography (AS-OCT) and in-vivo confocal microscopy (IVCM) imaging, may be more sensitive to identifying and monitoring epithelial downgrowth, compared with routine light biomicroscopy in patients undergoing penetrating keratoplasty, and will perhaps replace more invasive diagnostics in these patients.

Non-invasive imaging modalities, such as high-resolution anterior-segment optical coherence tomography (AS-OCT) and in-vivo confocal microscopy (IVCM) imaging, may be more sensitive to identifying and monitoring epithelial downgrowth, compared with routine light biomicroscopy in patients undergoing penetrating keratoplasty, and will perhaps replace more invasive diagnostics in these patients, according to a recent case review retrospective study published in the November issue of Cornea.

Michael C. Chen, MD, of the University of California, Davis, and fellow researchers, conducted a retrospective case review on two eyes in two patients who had a history of multiple penetrating keratoplasties that developed epithelial downgrowth 4 and 6 months after the most recent penetrating graft.

The first patient was a 48-year-old man with a history of Acanthamoeba keratitis, who developed epithelial downgrowth after undergoing two therapeutic grafts over a 1-year period. The second patient was a 40-year-old man with a history of a corneal laceration, complicated by fungal keratitis, who was diagnosed with epithelial downgrowth after undergoing three penetrating grafts, placement of a glaucoma drainage device, and pars plana vitrectomy over a 3-year period. In both cases, high-resolution AS-OCT imaging identified-at the level of the endothelium-a highly reflective layer and IVCM images revealed round hyperreflective nuclei consistent with epithelium.

To access this study, click here.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.